All Online
Maximum 50 words to introduce the activity The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm.
Practice-changing updates to the medical literature that are hot off the presses! Join Dr. Pam Kushner to discuss important changes in the 2021 ADA guidelines and examine recently published research on atrial fibrillation, lipids, reducing cardiovascular risk, coconut oil, patient communication, and much more!
The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs.
Addressing “Diabesity”: Weight Loss as a Key Therapeutic Goal in the Management of T2DM (Module 1)
An Interactive Learning Experience From ArcheMedX This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
The Role of GIP and GLP-1 in the Pathophysiology of T2DM and Why it Matters (Module 2)
An Interactive Learning Experience From ArcheMedX This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
Hitting Diabetes Head-on: Improving Outcomes and Reducing Therapeutic Inertia With GLP-1 Receptor Agonists: AdaptED Module 1
An Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm. Learners will have the opportunity to evaluate their knowledge through multiple-choice and matching questions and case-based application.
Updates From the 2021 EASD and ADA Annual Meetings on Dual GIP/GLP-1 RA Therapy: What You Should Know (Module 3)
An Interactive Learning Experience From ArcheMedX This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
Hitting Diabetes Head-on: Improving Outcomes and Reducing Therapeutic Inertia With GLP-1 Receptor Agonists: AdaptED Module 2
An Interactive Learning Experience This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm. Learners will have the opportunity to evaluate their knowledge through multiple-choice and matching questions and case-based application.
